N'-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | 1363402-44-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N'-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• 英文别名: Vilzemetkib；1-N'-[4-[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6-methoxyquinolin-4-yl]oxy-3-fluorophenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• CAS: 1363402-44-1
• 化学式: C₃₆H₃₆F₂N₄O₅
• 分子量: 642.702
• InChiKey: IXDALXNUFGTEMF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  47
• 可旋转键数：
  12
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• Compounds As c-Met Kinase Inhibitors
  申请人：Chen Guoqing Paul

  公开号：US20120123126A1

  公开（公告）日：2012-05-17

  The present invention relates to compounds, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with the inhibition of the protein tyrosine kinase activity of growth factor receptors such as c-Met, thereby making them useful as anticancer agents, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.

  本发明涉及化合物、其制备方法、含有它们作为活性成分的药物组合物、用于治疗与抑制生长因子受体蛋白酪氨酸激酶活性相关的疾病状态的方法，如c-Met，从而使它们有用作抗癌剂，以及它们作为药物在生产中用于抑制酪氨酸激酶减少在温血动物如人类中的作用。
• [EN] USE OF COMPOUND AS C-MET KINASE INHIBITOR FOR TREATMENT OF NEUROFIBROMATOSIS TYPE I<br/>[FR] UTILISATION D'UN COMPOSÉ COMME INHIBITEUR DE LA KINASE C-MET POUR LE TRAITEMENT DE LA NEUROFIBROMATOSE DE TYPE I<br/>[ZH] 作为c-Met激酶抑制剂的化合物治疗I型神经纤维瘤病的用途
  申请人：[en]CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.;[zh]正大天晴药业集团股份有限公司

  公开号：WO2022268158A1

  公开（公告）日：2022-12-29

  c-Met激酶抑制剂的化合物制备治疗I型神经纤维瘤病药物的用途，具体涉及N-(4-((7-((1-(环戊烷基氨基)环丙烷基)甲氧基)-6-甲氧基喹诺林-4-基)氧基)-3-氟苯基)-N-(4-氟苯基)环丙烷-1,1-二甲酰胺制备治疗I型神经纤维瘤病药物的用途和方法。
• EP3766870A1
  申请人：——

  公开号：EP3766870A1

  公开（公告）日：2021-01-20
• CRYSTALLINE OF COMPOUND AS C-MET KINASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF
  申请人：CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.

  公开号：US20210047272A1

  公开（公告）日：2021-02-18

  The present application falls within the field of medicinal chemistry, relates to the crystalline of a compound as a c-Met kinase inhibitor, and specifically relates to the crystalline of N-(4-((7-((1-(cyclopentylamino)cyclopropyl)methoxy)-6-methoxyquinolin-4-yl)oxy)-3-fluorophenyl)-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and a preparation method therefor, a crystalline composition thereof, and a pharmaceutical composition thereof, as well as the use of the crystalline for treating diseases associated with the inhibition of growth factor receptor protein tyrosine kinase activity. The crystalline of the present application has excellent properties in at least one of the following aspects: pharmacokinetics, bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, etc.
• US8664244B2
  申请人：——

  公开号：US8664244B2

  公开（公告）日：2014-03-04